10 CMS and FDA Actions Affecting Care in 2026 - Takeaways - MDSpire

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.

  • By

  • Conexiant News Staff

  • July 10, 2026

  • 7 min

Share

  • 1

    The 2026 Medicare Physician Fee Schedule final rule establishes separate conversion factors for qualifying and nonqualifying alternative payment model participants.

  • 2

    The 2026 Medicare Advantage and Part D final rule implements changes to prescription drug coverage and eliminates cost-sharing for certain adult vaccines.

  • 3

    CMS finalized a 2.6% update to payment rates for hospital outpatient services and ambulatory surgical centers meeting quality reporting requirements.

  • 4

    The FDA approved Foundayo, an oral GLP-1 therapy, for weight management in adults with obesity or overweight and related comorbid conditions.

  • 5

    The FDA cleared Dexcom’s Stelo Glucose Biosensor System for over-the-counter use by children aged 2 years and older who do not use insulin.

Original Source(s)

10 CMS and FDA Actions Affecting Care in 2026

  • by Conexiant News Staff

  • July 10, 2026

Related Content

Side Effects: Sour Mouth, Lower BP

Acidic gum beat sugar-free at cranking out nitric oxide from beetroot juice — exactly backward from what test-tube studies predicted. Also this week: a sleep gene that ignores amyloid, and jackfruit sap moonlighting as a bone-building drug delivery system.

GLP-1 Drugs Tied to Smell, Taste Changes

A matched electronic health record study of more than 876,000 patients with type 2 diabetes found a low absolute incidence but higher relative hazard of documented smell and taste disturbances among patients prescribed glucagon-like peptide-1 receptor agonists.

Do Revisions in Rotator Cuff Repair Decline With GLP-1 Use?

Preoperative use was associated with fewer revisions and no increase in short-term complications among patients with obesity, although benefits appeared concentrated in select subgroups.